This paper focuses on coprecipitation of pyrazinamide (PZA) with polyvinylpyrrolidone (PVP) using gas antisolvent (GAS) process. Solutions of PZA/polymer in solvent mixtures (acetone and ethanol) with an overall concentration of 20 mg/ml were prepared. The process parameters: pressure, temperature, antisolvent addition rate, solvent composition, and polymer-drug ratio were manipulated to simplify the obtainability of controlled morphology and particle size distribution. Solvent-free particles with reduced crystallinity were precipitated having mean sizes between 311 and 1474 nm. Furthermore, the operating pressure and polymer-drug ratio stood as key parameters affecting the PVP/PZA particle size. The knowledge of the particle characteristics was the main objective in order to identify the crystalline phase and physicochemical properties of the final product. The drug release analyses revealed that by tuning the operating parameters, dissolution rate of PVP/PZA particles could reach near 90%, which was 2.5 times faster than the unprocessed PZA and thus facilitated drug assimilation through the organism.

本文重点研究吡嗪酰胺 (PZA) 与聚乙烯吡咯烷酮 (PVP) 使用气体反溶剂 (GAS) 工艺共沉淀。制备总浓度为20mg/ml的PZA/聚合物在溶剂混合物（丙酮和乙醇）中的溶液。控制工艺参数：压力、温度、反溶剂添加速率、溶剂组成和聚合物-药物比，以简化受控形态和粒度分布的可获得性。结晶度降低的无溶剂颗粒沉淀出平均尺寸在 311 和 1474 nm 之间。此外，操作压力和聚合物药物比是影响 PVP/PZA 粒径的关键参数。颗粒特性的知识是确定最终产品的结晶相和物理化学性质的主要目标。药物释放分析表明，通过调整操作参数，PVP/PZA 颗粒的溶出率可以达到接近 90%，比未加工的 PZA 快 2.5 倍，从而促进药物通过生物体的同化。